Clinical trial 8951-CL-0301
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
| Cancers | |
|---|---|
| Organ | Stomach - Duodenum-esogastric junction |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Astellas |
| EudraCT Identifier | 2017-002567-17 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03504397 |
| Inclusion criteria | Unresecable or metastatic |
| Last update |